- Cell Therapeutics, Inc. (CTI) Closes PGT305 (PIONEER) Lung Cancer Clinical Trial; New PGT306
Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC) today announced that the Company and the Data Safety Monitoring Board (DSMB) agreed to close the PGT305 PIONEER lung cancer clinical trial and take patients off both treatment arms. - First Mobetron In China To Be Used In New National Lung Cancer Initiative
IntraOp Medical Corporation (OTCBB: IOPM), a provider of innovative technology solutions for the treatment and eradication of cancer - Common Virus Significantly Enhances Cancer-Fighting Ability Of Standard Chemotherapy Drugs
Can a common virus boost the cancer-killing abilities of existing cancer drugs? A preclinical study presented at this year's EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics, in Prague, Czech Republic concluded that the answer is "yes." - Gene Expression Profiling Not Quite Perfected In Predicting Lung Cancer Prognosis
While there have been significant advances in the use of gene expression profiling to assess a cancer prognosis, a Mayo Clinic review and analysis of existing lung cancer studies shows that this technology has not yet surpassed the accuracy of conventional methods used to assess survival in lung cancer patients. - Lung Cancer Alliance Launches Early Detection Web Site To Educate Those At Highest Risk
The Lung Cancer Alliance (LCA) launched screenforlungcancer.org, a new Web site aimed at educating people at risk for lung cancer about the importance of yearly low-dose Computed Tomography (CT) screening to promote early detection of the disease. - RTA 402 Shown To Prevent Development Of Lung Cancer
Reata Pharmaceuticals, Inc. today announced the presentation of preclinical data showing that RTA 402 prevented the development of lung cancer in an established mouse model of the disease. This data, produced in the laboratory of Dr. Michael Sporn from the Dartmouth Medical School, was discussed in an oral presentation at the AACR Frontiers in Cancer Prevention Meeting being held in Boston, MA. - New Treatment Finds Success, Long Survival In Treating Tiniest Lung Tumors,
Patients with metastatic cancer tumors in their lungs are much more likely to live disease-free if they have an experimental treatment involving shaped-beam radiosurgery rather that conventional treatment, according to a University of Rochester Medical Center study. - Vaccination With Embryonic Stem Cells Prevents Lung Cancer In Mice
Researchers in America have discovered that vaccinating mice with embryonic stem cells prevented lung cancer in those animals that had had cancer cells transplanted into them after the vaccination or that had been exposed to cancer-causing chemicals. - Women Catching Up To Men In Lung Cancer Deaths
Lung cancer is the No. 1 cancer-related killer in the United States. And while men are more likely to die from lung cancer than women, the trend is starting to change. - Radiation After Surgery Doubles Survival Time For Some Lung Cancer Patients
Patients with lung cancer that has spread to mediastinal lymph nodes - located between the chest, breastbone and spine - who receive radiation after surgery and chemotherapy live twice as long as patients who do not receive radiation after surgery, according to a study presented at the plenary session November 6, 2006, at the American Society for Therapeutic Radiology and Oncology's 48th Annual Meeting in Philadelphia. - Updated Analysis Demonstrates Long-Term Survival Benefit Of EFAPROXYN(TM) In Treating NSCLC Patients
Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced the presentation of updated results from its Phase 2 multi-center study of EFAPROXYN (efaproxiral) in patients with unresectable non-small cell lung cancer (NSCLC) receiving sequential chemoradiotherapy (S-CRT). - Poniard Announces Positive Interim Survival Results From Ongoing Phase 2 Trial Of Picoplatin
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a specialty pharmaceutical company focused on oncology, today announced positive interim median overall survival data from its ongoing Phase 2 clinical trial of picoplatin in patients with small cell lung cancer (SCLC). - Hecht Honored With AACR-Cancer Research And Prevention Foundation Award For Ground-breaking Research
Stephen S. Hecht, an internationally recognized expert on cancer-causing agents in tobacco and the pathways by which they cause cancer, has been selected to receive the fifth annual American Association for Cancer Research (AACR)-Cancer Research and Prevention Foundation (CRPF) Award for Excellence in Cancer Prevention Research. - Accuray Introduces First And Only Radiosurgery Products Designed For The Non-Invasive Treatment
Accuray Incorporated, the global leader in the field of robotic radiosurgery, today introduced three new products designed to improve the way lung cancer is treated. These products -- Xsight(TM) Lung Tracking System, Xchange(TM) Robotic Collimator Changer and 4D Treatment Optimization and Planning System . - Minister Launches Lung Cancer Awareness Month, UK
To highlight the symptoms of lung cancer health minister Rosie Winterton today launched Lung Cancer Awareness Month at the Royal Mail's South London Mail Centre, where she heard first hand the experiences of lung cancer patients and met representatives from Royal Mail, the voluntary sector and health professionals. - Three New Lung Tumor Subtypes Identified In DNA Profiling Study
A new study has identified three subtypes of non-small-cell lung cancer tumors, a finding that may provide valuable clinical information about patient survival in early- or late-stage disease, how likely the cancer is to spread and whether the tumor will prove resistant to chemotherapy. - Lung Cancer Alliance-Georgia Issues Inaugural State-Specific Report Card On Lung Cancer
Today, Lung Cancer Alliance-Georgia (LCA-GA) issued its first-ever state-specific Report Card on Lung Cancer, an assessment of progress being made against this lethal disease in the state of Georgia. LCA-GA is a chapter of Lung Cancer Alliance, the only national organization solely dedicated to patient support and advocacy for people living with or at risk for lung cancer. - DNA Profiling Study Identifies Three New Lung Tumor Subtypes
A new study has identified three subtypes of non-small-cell lung cancer tumors, a finding that may provide valuable clinical information about patient survival in early- or late-stage disease, how likely the cancer is to spread and whether the tumor will prove resistant to chemotherapy - Lung Cancer Symptoms Have Not Changed
Despite technologic advances, the presenting symptoms of lung cancer (LC) have not changed over time, according to a new study. - Radiofrequency Ablation In Inoperable Lung Cancer Yields Results
Patients with lung cancer who were deemed medically inoperable showed mid-to-long-term results when treated with radiofrequency ablation (RFA), according to new research. - Radiation To Healthy Lung Associated With Pulmonary-Related Death
A new study reveals that fatal pulmonary-related events following radiation therapy are associated with the amount of radiation received by the contralateral or healthy lung. - Air Flow Obstructions May Predict Lung Lesions
New research suggests that airflow obstructions determined by spirometry may predict premalignant lung lesions. Using a cohort of subjects who visited lung cancer screening clinics from 1996 to 2005, researchers from the Roswell Park Cancer Institute in New York analyzed the relationship between spirometric parameters of airflow obstruction and central premalignant lung lesions. - Hadassah Physician Participates In Lung Cancer Breakthrough
The results of an international research study published today in the New England Journal of Medicine report that an annual low-dose CT scan can detect lung cancer in its earliest stage in 85 percent of patients, and when followed by prompt surgical removal, 92 percent have a 10-year survival rate. - Vion Pharmaceuticals Presents Initial Data From A Phase II Trial Of Cloretazine(R) (VNP40101M)
Vion Pharmaceuticals, Inc. (Nasdaq: VION) will present data today at The Fourth International Chicago Symposium on Malignancies of the Chest and Head & Neck in a poster session on its lead anticancer agent Cloretazine(R) (VNP40101M) as a single agent in a Phase II trial in patients with relapsed or refractory small cell lung cancer. The exhibits are being displayed at The Sheraton Chicago Hotel in the Chicago Ballrooms VIII, IX, & X from 7:30 a.m. to 7:30 p.m. - EntreMed Commences Clinical Trial For MKC-1 In Lung Cancer Patients
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced commencement of a multi-center study with its drug candidate, MKC-1, in non-small cell lung cancer (NSCLC) patients. - Lung Cancer 10-Year Survival Dramatically Improves With Annual CT Screening And Prompt Treatment
Lung cancer can be detected at its very earliest stage in 85 percent of patients using annual low-dose CT screening, and when followed by prompt surgical removal, the 10-year survival rate is 92 percent. These results, to be reported in the October 26 New England Journal of Medicine, would dramatically decrease the number of deaths from lung cancer -- the number one cause of cancer deaths among both men and women in the U.S. - Lilly Launches Phase III 'GALES' Trial Of ALIMTA® (Pemetrexed For Injection) In Small Cell Lung
Eli Lilly and Company has launched a major clinical trial evaluating ALIMTA (pemetrexed for injection) in extensive-stage small cell lung cancer (SCLC), a devastating and rapidly spreading form of lung cancer. - International Conference Focuses On A Rare And Lethal Lung Cancer
The University of Chicago's Pritzker School of Medicine hosted the eighth conference of the International Mesothelioma Interest Group (IMIG) from Thurs., Oct. 19, through Sun., Oct. 22, 2006, at the Sheraton Chicago Hotel and Towers, 301 E. North Water Street in Chicago. - Lilly Launches Phase III 'GALES' Trial Of ALIMTA(R) (Pemetrexed For Injection) In Small Cell Lung
Eli Lilly and Company has launched a major clinical trial evaluating ALIMTA (pemetrexed for injection) in extensive-stage small cell lung cancer (SCLC), a devastating and rapidly spreading form of lung cancer. This international trial, expected to be the largest ever to be conducted in SCLC(1), will assess the potential clinical benefit of pemetrexed in combination with carboplatin, a commonly-used chemotherapeutic agent. - FDA Approves New Drug For Advanced Lung Cancer
Promising results from a clinical trial led by lung cancer specialist, Alan Sandler, M.D., director of Thoracic Oncology at Vanderbilt-Ingram Cancer Center, have helped in the effort to get a new drug approved by the Food and Drug Administration to fight an advanced form of the disease. - Avastin Approved In US For First-line Treatment Of Most Common Form Of Lung Cancer
Roche announced that following yesterday's FDA approval in the US, Avastin will now benefit patients suffering from advanced non-small cell lung cancer (NSCLC)* - the most common form of this devastating disease. The approval is based on the pivotal Phase III trial data (E4599) which showed a strong survival benefit for patients treated with Avastin in combination with a platinum-based chemotherapy (carboplatin plus paclitaxel) compared to chemotherapy alone. - Key To Lung Cancer Chemo Resistance Revealed
Scientists at Johns Hopkins have discovered how taking the brakes off a “detox” gene causes chemotherapy resistance in a common form of lung cancer. - Avastin Approved By FDA For Lung Cancer Combination Treatment
The FDA has approved the use of Avastin for lung cancer combination treatment with carboplatin and paclitaxel chemotherapy for first line treatment. Avasting is now approved for the most common lung cancer - locally advanced, recurrent or metastatic, non-squamous, non-small cell lung cancer (NSCLC). - Lung Cancer May Be Hereditary, Study Shows
People who have a family history of lung cancer are at nearly double the risk of developing the disease themselves, according to new research. In a large-scale, population-based cohort, Japanese researchers studied the association between family history of lung cancer and subsequent risk. - KEAPing Tumor Cells Susceptible To Chemotherapy
Lung cancer is the most common cause of cancer-related death worldwide, in part because these tumors often are or become resistant to chemotherapy. A study by Shyam Biswal and colleagues, published in the international open-access journal PLoS Medicine, now shines some light on what causes this resistance. - Impaired Gene Helps Nonsmall-Cell Lung Cancer Resist Drug
Lung cancer cells with a defective version of a potential tumor suppressor gene are highly resistant to attack by a platinum-based drug commonly used to treat the disease, researchers at The University of Texas M. D. Anderson Cancer Center and The University of Texas Southwestern Medical Center at Dallas report in the cover article of the Oct. 1 edition of Cancer Research. - Increased Risk Of Lung Cancer Caused By Proximity To Heavy Industry
Living close to heavy industry may increase the risk of developing lung cancer, although the effect is relatively modest, suggests research published ahead of print in Thorax. - Introgen's INGN 241 Works Synergistically With Avastin(R) To Cut Blood Supply To Cancers
Introgen Therapeutics, Inc. (Nasdaq: INGN) reported data from preclinical studies in which mda-7, the active component of INGN 241, in combination with Avastin(R) (Bevacizumab), produced a complete and synergistic therapeutic effect in models of lung cancer. - Northwest Biotherapeutics Receives FDA Clearance For Lung Cancer Trial
Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBT.OB) today announced that it has received FDA clearance to proceed with Phase I clinical testing of its personalized therapeutic cancer vaccine, DCVax(R)-LB, in non-small cell lung cancer. The clinical endpoints of the trial will be progression-free survival (i.e., delay in progression of the cancer) and overall survival. - Lung Cancer Survival Rate Improved By Modern Radiation
Modern three-dimensional radiation therapy has been proven to be more successful at curing lung cancer than older two-dimensional radiation therapy for some patients with early stage lung cancer, according to a new study in the September 1, 2006 edition of the International Journal of Radiation Oncology * Biology * Physics, the official journal of the American Society for Therapeutic Radiology and Oncology (ASTRO). - Modern Radiation Therapy Ups Lung Cancer Survival
Modern three-dimensional radiation therapy has been proven to be more successful at curing lung cancer than older two-dimensional radiation therapy for some patients with early stage lung cancer, according to a new study in the September 1, 2006 edition of the International Journal of Radiation Oncology * Biology * Physics, the official journal of the American Society for Therapeutic Radiology and Oncology (ASTRO). - Poniard Pharmaceuticals Completes Enrollment In Picoplatin Phase 2 Small Cell Lung Cancer Clinical
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a specialty pharmaceutical company focused on oncology, today announced that the Company has completed enrollment in a Phase 2 open-label, multi-center clinical trial evaluating picoplatin for the treatment of small cell lung cancer (SCLC). All 75 patients targeted for enrollment have been treated with picoplatin, the Company's lead product candidate.
|
